Peptide Library

Human study PLS-00053

Diagnostic relevance of Humanin, GAS5 and miR-21/miR-103 in prostate disease risk stratification.

Cross-sectional study · 375 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Diagnostic relevance of Humanin, GAS5 and miR-21/miR-103 in prostate disease risk stratification.primary · Clinical and experimental medicine · 2025-08-06 · PMID 40768089 · DOI

Design and participants

Design
Cross-sectional study
Population
Male patients suspected of prostate cancer, stratified into benign prostatic hyperplasia, precancerous lesions and prostate cancer
Conditions
Benign prostatic hyperplasia, Prostatic precancerous lesions, Prostate cancer
Planned enrollment (registry)
Not reported
Enrolled
375
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The authors concluded that a combined panel of circulating Humanin, MOTS-c and GAS5 plus exosomal miR-21/miR-103 is a promising non-invasive biomarker approach for risk stratification of prostate diseases.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: MOTS-c was measured only as an endogenous circulating biomarker. It was never administered, so no intervention effect can be inferred.
    • abstract only: Only the abstract is available in the record, and methods details such as recruitment and the assays are not described.
    • inappropriate endpoint: Endogenous biomarker levels were measured for diagnosis; no MOTS-c was given and no clinical outcome was assessed.
    • inappropriate population: Patients with suspected prostate cancer are not an obesity, insulin resistance or diabetes population.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 40768089, abstract (final two sentences) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 40768089, abstract (sentences 1 and 4-5) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 40768089, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 40768089, abstract (sentences 1 and 3) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).